Clinical Trials on Unresectable Gastrointestinal Stromal Tumor (GIST) in South Africa

Total 122 results

Novartis Pharmaceuticals

Completed

A Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)

Gastrointestinal Stromal Tumor (GIST)

China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
Australasian Gastro-Intestinal Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Scandinavian...

Active, not recruiting

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)

Gastrointestinal Stromal Tumour

Singapore, Norway, Finland, Australia, Sweden, France, United Kingdom, Spain, Netherlands, Slovakia
Pfizer

Completed

A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

Gastrointestinal Stromal Tumor

United States, Australia, Belgium, Italy, Singapore, Spain, Switzerland, United Kingdom, Canada, France, Netherlands
European Organisation for Research and Treatment...
UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma Group

Completed

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

France, Australia, United Kingdom, Germany, Denmark, Spain
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

United States
Daiichi Sankyo, Inc.
Merck Sharp & Dohme LLC; Plexxikon

Terminated

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Melanoma | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Gastrointestinal Stromal Tumor (GIST)

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology...

Terminated

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0502)

Gastrointestinal Stromal Tumor

United States, Canada
RemeGen Co., Ltd.

Completed

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Metastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid Tumor

Australia
AB Science

Terminated

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

United States, France, Lebanon
Spago Nanomedical AB

Recruiting

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad)

Solid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Novartis Pharmaceuticals

Completed

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (INV555)

Gastrointestinal Stromal Tumors

Saudi Arabia, Taiwan, Turkey, Egypt, Thailand, Russian Federation, South Africa, Lebanon, India, Tunisia, Algeria, Jordan
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
Erasmus Medical Center

Completed

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (REGORA)

Colorectal Neoplasms | Gastrointestinal Stromal Tumors

Netherlands
Western Sydney Local Health District

Recruiting

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study (ANZ UGI)

Gastric Cancer | Esophageal Neoplasms | Neuroendocrine Tumors | Gastric Adenocarcinoma | Cancer of Stomach | Oesophageal Cancer | Gastric Neoplasm | GIST | GI Cancer

Australia
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified

United States
Pfizer

Completed

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

Gastrointestinal Stromal Tumors

Korea, Republic of
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Grupo Espanol de Investigacion en Sarcomas

Recruiting

Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK ((SELNET))

Gastrointestinal Stromal Tumors | Soft-tissue Sarcoma | Bone Sarcoma

France, Spain, Argentina, Costa Rica, Brazil, Italy, Mexico, Peru
Deciphera Pharmaceuticals LLC

Active, not recruiting

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (INTRIGUE)

Gastrointestinal Stromal Tumors

United States, Korea, Republic of, Norway, Spain, Netherlands, Australia, Taiwan, France, United Kingdom, Belgium, Singapore, Canada, Italy, Poland, Sweden, Hungary, Germany, Israel, Czechia, Argentina, Chile, Switzerland
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Pfizer

Approved for marketing

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Gastrointestinal Neoplasm

United States, Australia, Italy, Argentina, Colombia, Czech Republic, Korea, Republic of, Poland, Slovakia, Spain, Turkey, Denmark, Taiwan, Mexico, Belgium, Germany, Thailand, United Kingdom, Switzerland, Chile, Hong Kong, India, Si... and more
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States, Puerto Rico, Canada, Australia, New Zealand, Netherlands, Saudi Arabia, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Paul G. Kemps, MD
Juliana Children's Hospital

Active, not recruiting

GastroIntestinal Cancer in Children and Adolescents (GICCA)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Burkitt Lymphoma | Neuroendocrine Tumors | Gastrointestinal Cancer | Hepatoblastoma

Netherlands
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
Pfizer

Completed

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Hepatocellular Carcinoma | Advanced Breast Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Metastatic Renal Cell Cancer | Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Gastrointestinal Stromal Tumor | Advanced Gastric Cancer | Metastatic Castration Resistant Prostate Cancer | Advanced... and other conditions

United States, Spain, Korea, Republic of, France, Australia, United Kingdom, Canada, Brazil, Argentina, Taiwan, Belgium, Colombia, Germany, Hong Kong, Mexico, Philippines, Singapore
BeiGene

Recruiting

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

China, United States, Australia, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Adult Type Ovarian Granulosa Cell Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor

United States, Japan
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

Unresectable Metastatic Colorectal Cancer

Israel, United States, Japan, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Metastatic Digestive System Neuroendocrine Tumor G1 | Recurrent Digestive System Neuroendocrine Tumor G1 | Regional Digestive System Neuroendocrine Tumor G1 | Metastatic Neuroendocrine Tumor | Midgut Neuroendocrine Tumor G1 | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine Tumor | Neuroendocrine...

Canada, United States
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company; European Network of Gynaecological Oncological Trial... and other collaborators

Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO)

Low Grade Serous Ovarian Carcinoma | Adult Type Granulosa Cell Tumor

Belgium, Netherlands, France
The Queen Elizabeth Hospital
Novartis; Amgen

Completed

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer (PIE)

Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal

Australia
Erasmus Medical Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Recruiting

Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy (FIBROPANC-1)

Pancreatic Fistula | Pancreas Neoplasm | GIST | Neuroendocrine Carcinoma of Pancreas | Duodenum Carcinoma | Distal Cholangiocarcinoma | Pancreas Fibrosis

Netherlands
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
Duke University
Merck Sharp & Dohme LLC; Ipsen

Completed

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)

Gastroenteropancreatic Neuroendocrine Tumors

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
Pfizer

Completed

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Metastatic or Unresectable Cutaneous Melanoma

United States, Spain, Canada, Italy, United Kingdom, Germany, Korea, Republic of, France, Australia, Czechia, Russian Federation, Turkey, Israel, Netherlands, Greece, Hungary, Japan, Portugal, Argentina, Austria, Belgium, Brazil, Po... and more
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States

Clinical Trials on Unresectable Gastrointestinal Stromal Tumor (GIST) in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations